Меню
Идёт набор NCT05626426

Electrical Stimulation for the Treatment of Optic Neuropathies

Без фазы С лечением Glaucoma Glaucoma, Open-Angle Optic Nerve Diseases

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Repetitive, Transorbital Alternating Current Stimulation (rtACS).
Кому может быть актуально
Состояния в реестре: Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

An Open-Label Study to Evaluate the Safety and Efficacy of Repetitive, Transorbital Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies

Обзор

The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.

Подробное описание

This is a concurrent open-label study for patients who are deemed safe to participate in the electrical stimulation trial but do not fit the exact criteria for the randomized clinical trial.

Вмешательства

  • Устройство Repetitive, Transorbital Alternating Current Stimulation (rtACS)
    Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina

Первичные конечные точки

  • Change from baseline in visual field assessed by Humphrey Visual Field Index (VFI). [Срок оценки: Baseline through 6 months]
  • Change from baseline in visual field assessed by Humphrey Mean Deviation (MD). [Срок оценки: Baseline through 6 months]
Вторичные конечные точки (8)
  • Change from baseline in ganglion cell layer as measured by optical coherence tomography (OCT, visible light and/or infrared). [Срок оценки: Baseline through 6 months]
  • Change from baseline in nerve fiber layer thickness as measured by optical coherence tomography (OCT, visible light and/or infrared). [Срок оценки: Baseline through 6 months]
  • Change from baseline in visual acuity as assessed by the Snellen visual acuity test. [Срок оценки: Baseline through Month 6]
  • Change from baseline in visual evoked potential. [Срок оценки: Baseline through Month 6]
  • Change from baseline in retinal metabolic analysis(RMA)/OcuMet imaging. [Срок оценки: Baseline through Month 6]
  • Change from baseline in adaptive optics retinal imaging. [Срок оценки: Baseline through Month 6]
  • Change from baseline in laser speckle flowgraphy [Срок оценки: Baseline through Month 6]
  • Change from baseline in OCT angiography [Срок оценки: Baseline through Month 6]

Критерии участия

Критерии включения

  • Participant must be at least 18.
  • Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).
  • Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false postivies do not exeed 20%.
  • In the opinion of the investigator the participant's eye pressure must be clinically stable.
  • If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.
  • Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

Критерии исключения

  • Participant is unable to comply with study procedures or follow-up visits.
  • Participant has a history of ocular herpes zoster.
  • Participant has pathological nystagmus
  • Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa.
  • Participant has evidence of corneal opacification or lack of optical clarity.
  • Participant has uveitis or other ocular inflammatory disease.
  • Participant has any electric or electroinc implants such as a pacemaker.
  • Participant has acute conjunctivitis.
  • Participant has acute autoimmune disease.
  • Participant is pregnant or lactating.
  • Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia.
  • Unresected brain tumors
  • Implanted intracranial magnetic metals (metallic implants in the head / skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable
  • Patients with any skin damage.
  • Children and comatose patients.
  • Patients with history of epileptic seizure within the last 10 years.
  • Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
  • Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and/or unable to confirm follow-up participation
  • Prior participation in a vision training/stimulation study in the last 12 months

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • Byers Eye Institute — Palo Alto

Идентификаторы

NCT: NCT05626426 · 68207

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗